Effect of Switching From an Anti-Diabetic Loose Dose Combination to a Fixed Dose Combination Regimen at Equivalent Dosage for 6 Months on Glycemic Control in Japanese Patients With Type 2 Diabetes: A Pilot Study.
Effect of Switching From an Anti-Diabetic Loose Dose Combination to a Fixed Dose Combination Regimen at Equivalent Dosage for 6 Months on Glycemic Control in Japanese Patients With Type 2 Diabetes: A Pilot Study.
复制标题
DOI：
10.14740/jocmr3067w
复制
发表时间：
2017-08
期刊：
影响因子：
--
通讯作者：
Terauchi Y
中科院分区：
文献类型：
--
作者：
Aoki K;Nagakura M;Taguri M;Kamiyama H;Masumura M;Furuie T;Oka M;Kamiko K;Nakajima S;Akema N;Terauchi Y
2型糖尿病患者常长期服用多种降糖药物。固定剂量复方制剂（FDC）治疗有望改善糖尿病患者的药物依从性。尚未充分评价从松散剂量复方制剂（LDC）方案转换为等效剂量FDC方案对血糖控制的影响。因此，我们研究了日本2型糖尿病患者以等效剂量从LDC转换为FDC 6个月对血糖控制的影响。入组了38例正在服用抗糖尿病药物（包括吡格列酮+二甲双胍、吡格列酮+阿格列汀或吡格列酮+格列美脲）的日本2型糖尿病患者。将这些药物分别转换为同等剂量的Metact®、Liobel®或Sonias® FDC。如可能，研究期间未改变其他降糖药物和胰岛素单位。在从LDC转换为FDC后0、2、4和6个月测量HbA 1c和体重。我们还在FDC方案开始后2个月进行了问卷调查。与从LDC方案转换为FDC方案之前相比，第2、4和6个月时的HbA 1c水平无显著变化。此外，74.2%的患者认为减少药物数量“非常好”或“好”。在本研究中，接受等效剂量LDC和FDC治疗的患者之间的HbA 1c水平无差异。
Patients with type 2 diabetes mellitus often take multiple anti-diabetic drugs for a long period. Fixed dose combination (FDC) therapy is expected to improve drug adherence for patients with diabetes. The effect of switching from a loose dose combination (LDC) regimen to an FDC regimen at equivalent dosage on glycemic control has not been evaluated fully. Therefore, we investigated the effect of switching from LDC to FDC at equivalent dosage for 6 months on glycemic control in Japanese patients with type 2 diabetes. Thirty-eight Japanese patients with type 2 diabetes who were taking anti-diabetic drugs including pioglitazone + metformin, pioglitazone + alogliptin, or pioglitazone + glimepiride were enrolled. These drugs were switched to an FDC of Metact®, Liobel® or Sonias®, respectively, at equivalent dosage. Other anti-diabetic drugs and units of insulin were not changed during the study if possible. HbA1c and body weight were measured 0, 2, 4 and 6 months after switching from an LDC to FDC. We also conducted a questionnaire survey 2 months after the start of the FDC regimen. HbA1c levels at 2, 4, and 6 months were not significantly changed compared with prior to switching from an LDC to FDC regimen. Moreover, 74.2% of patients considered decreasing the number of drugs to be “very good” or “good”. HbA1c levels did not differ between patients receiving LDC and FDC therapy at equivalent dosage in this study.